Translational Antigen Discovery

Research Group Head

Antigen discoveries hold immense significance for the development of safe, precise, and effective cancer immunotherapies. The Faridi group uses leading edge technologies to uncover the role of Human Leukocyte Antigen (HLA) molecules in tumours, with the aim of developing novel targets for cancer immunotherapy.


Translational Antigen Discovery Research Group
Research Group

Focusing on the immune response and cancer treatment, the Translational Antigen Discovery laboratory’s research holds great promise for revolutionising cancer treatment with more targeted and effective approaches.

The group’s focus is identifying clinically relevant peptides presented by the Human Leukocyte Antigen (HLA) molecule to uncover potential targets for precision immunotherapies. The team’s quest involves employing a spectrum of advanced techniques, including mass spectrometry, proteomics, bioinformatics, multi-omics, and immunology, to meticulously piece together the puzzle of immune responses, with a specific emphasis on cancer-related aspects.

In this pursuit, the lab’s dedication to exploring immunopeptidomics – a specialised field within its arsenal – deserves special attention. Immunopeptidomics involves deciphering the intricate language of peptide antigens presented by HLA molecules, offering crucial insights into how the immune system recognises and responds to threats, especially in the context of cancer. By delving into the specifics of immunopeptidomics, the lab is exploring potential avenues for developing highly targeted immunotherapies for cancer and other diseases.

Projects in progress

Translational Antigen Discovery RG progress

Areas of focus

  • Finding soluble HLA as biomarkers to use for early cancer detection and as predictive indicators of immunotherapy effectiveness.
  • Leading the development of precision vaccines tailored for childhood cancers.
  • Developing immunopeptidomics and bioinformaticsmethods to identify non-canonical HLA-bound peptides, including spliced, endogenous retroviral, and non-coding RNA-derived peptides.

Major Collaborators

ProfessorGerald LinetteUniversity of PennsylvaniaPhiladelphiaUSA
ProfessorJavad NazarianThe DMG/DIPG CentreZurichSwitzerland
ProfessorRiccardo DolcettiSir Peter MacCallum Cancer CentreMelbourneAustralia
ProfessorTony PurcellMonash UniversityMelbourneAustralia
Associate ProfessorRalf SchittenhelmMonash UniversityMelbourneAustralia
Associate ProfessorOrazio VittorioChildren’s Cancer InstituteSydneyAustralia


Our research focus

Research Group